Amiko wins CE Mark to integrate drug sensor tech into inhalers

Amiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals‘ (NYSE:TEVA) Spiromax inhaler, Chiesi‘s Nexthaler device and GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler. The company’s Respiro platform is designed to help doctors monitor, in real-time, when and how well patients are using their medications. Get the full story at our sister site, Drug Delivery Business News. The post Amiko wins CE Mark to integrate drug sensor tech into inhalers appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat amiko chiesigroup GlaxoSmithKline plc Teva Pharmaceuticals Source Type: news

Related Links:

Thread Starter Have you gotten into Medicine and would like advice? Follow 1 minute ago now Quote: Originally Posted by ecolier I like Cognition more though :( Movement disorders interest me too. It would be so much easier if I picked Cardiology - it will definitel...
Source: The Student Room - Category: Universities & Medical Training Authors: Tags: Medicine Source Type: forums
Publication date: Available online 17 August 2018Source: Journal of Visceral SurgeryAuthor(s): T. Sarcher, B. Dupont, A. Alves, B. MenahemSummaryMultidisciplinary management of infra-peritoneal rectal cancer has pushed back the frontiers of sphincter preservation, without impairment of carcinological outcome. However, functional intestinal sequelae, grouping together several symptoms known under the name of anterior resection syndrome (ARS), have emerged and become an increasingly frequent concern for both patients and physicians. The pathophysiology is complex: ARS is a combination in various degrees of stool frequency, i...
Source: Journal of Visceral Surgery - Category: Surgery Source Type: research
ConclusionsThe current series is one of the largest reported experiences using ISB to identify injured lymphatics responsible for LC or LF. Lymphatic complications after a vascular procedure usually occur within 3 weeks of the index vascular procedure, with LF being identified and treated earlier than LC. ISB injection rapidly identifies disrupted extremity lymphatics. Ligation of these lymphatics results in reliable resolution of the lymphatic complication.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
ConclusionsCDT through an anterior tibial vein approach is a feasible, effective, and safe method for acute extensive lower extremity DVT patients. In addition, the anterior tibial vein approach can be an alternative to the traditional CDT approach.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
Publication date: Available online 17 August 2018Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): Micheal T. Ayad, David L. GillespieAbstractAnticoagulation is the cornerstone for the treatment of deep venous thrombosis and pulmonary embolism. On occasion, this is not possible because of bleeding complications or, rarely, breakthrough pulmonary embolism associated with this treatment method. The development of vena cava interruption in the 1970s was a critical advance in the treatment of these patients. Placement of inferior vena cava (IVC) filters has been steadily increasing since their intro...
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
ConclusionsThere is insufficient evidence to recommend GCS in conjunction with extended pharmacologic prophylaxis to prevent VTE in patients undergoing orthopedic and abdominal surgery. A clinical trial directly investigating this important subject is needed.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
ConclusionExploring perspectives in LARS patients resulted in the identification of potential improvements in current care pathways. Recommendations on ways to improve information provision, screening of LARS and methods to intervene in the gap of supportive care after discharge are presented. We recommend to implement these measures as QoL of patients undergoing colorectal cancer surgery may be improved.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: September 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 9Author(s):
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
In this study, we compared perioperative and oncologic outcomes of patients treated with either open or robot-assisted radical cystectomy and intracorporeal neobladder at a tertiary care center.MethodsThe institutional prospective bladder cancer database was queried for “cystectomy with curative intent” and “neobladder”. All patients underwent robot-assisted radical cystectomy and intracorporeal neobladder or open radical cystectomy and orthotopic neobladder for high-grade non-muscle invasive bladder cancer or muscle invasive bladder cancer with a follow-up length ≥2 years were included. A 1:1 pr...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionBoth types of organ-sparing surgeries assessed in this study achieved good outcomes, in terms of the aesthetics, sexual functions, urinary functions, and HRQOL in patients, without compromising the therapeutic effects of these surgeries. However, the observed decreases in orgasmic function will need to be addressed further.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Medical Devices | Respiratory Medicine